FORT LAUDERDALE, Fla., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that Mark Pomeranz, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference.
| H.C. Wainwright 25th Annual Global Investment Conference | |
| Presentation Date: | Monday, September 11, 2023 at 7:00 AM ET |
| Meetings: | Management is participating in virtual investor meetings on September 11 – 14, 2023 |
| Webcast: | https://journey.ct.events/view/d901ec90-604f-458e-8973-a36787a54f8e |
A replay of the webcast will be archived on the Events page on the company’s website, www.motusgi.com and will be available for 90 days.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Investor Contact:
Troy Williams
LifeSci Advisors
(518) 221-0106
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.00 |
| Daily Volume: | 0 |
March 18, 2024 February 22, 2024 February 21, 2024 November 13, 2023 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
